Video
The importance of incorporating the patient’s voice when developing new treatments
Author(s):
“We need to understand what the treatment [means] to them as individuals, and how they perceive the benefit of the treatment,” says Cornelia Haag, Molkenteller, MD, PhD.
Video Player is loading.
In this video, Cornelia Haag-Molkenteller, MD, PhD, discusses the takeaways of the study, “Once-daily vibegron 75 mg for overactive bladder: Long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR).” Haag-Molkenteller is a chief medical officer at Urovant Sciences, Inc in Irvine, California.
Related Videos
Anna Myers, CNP, discusses her approach to preventing UTIs
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Ian Metzler, MD, on the increasing prevalence of kidney stones in women
How pre-URS tamsulosin use in pediatric patients may reduce repeat procedures
An expert discusses patient counseling in wake of FDA’s labeling changes for testosterone
Ekene Enemchukwu, MD, on vaginal estrogen for genitourinary syndrome of menopause
Expert discusses innovations in single-use ureteroscopes for stones
Naeem Bhojani, MD, discusses WATER III data on Aquablation vs enucleation for BPH
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Related Content
